<i>In Vivo</i> Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043
Nannan Zhou(Chinese Academy of Sciences), Pin‐Fang Lin(Bristol-Myers Squibb (United States)), Yi-Fei Gong(Bristol-Myers Squibb (United States)), Richard J. Colonno(Assembly Biosciences (United States)), Beata Nowicka-Sans(Bristol-Myers Squibb (United States)), John F. Kadow(Bristol-Myers Squibb (United States)), David R. Langley(Bristol-Myers Squibb (United States)), George J. Hanna(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fan Li(Bristol-Myers Squibb (United States)), Tao Wang(Anhui Jianzhu University), Fang Hua(Harbin Medical University), Louis Alexander(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), Jie Fang(Chinese Academy of Sciences), Mark Krystal(ViiV Healthcare (Spain)), Sharon Zhang(Bristol-Myers Squibb (United States))
Cited by 54
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239